Ethics in Clinical Proteomics

What is clinical proteomics?

The proteome is the set of proteins produced by an organism at a given time. The proteome reflects the transcriptome and is also influenced by other factors, such as oncogenic activation, chromosome imbalances, and translation errors. In recent years, proteomics has emerged as an exciting area of scientific and medical research due to its implications for the development of diagnostic and prognostic markers of disease and therapeutic targets for a wide range of diseases such as cancer, infectious diseases, and immune rejection after transplantation.

Biomarker Test

Image Credit: 

Applications of proteomics

Proteomics can be used to investigate several biological activities and states, it can tell us when and where proteins are expressed; calculate the rates of protein production, degradation, and steady-state abundance; reveal how proteins are modified; demonstrate the movement of proteins between subcellular structures; describe the involvement of proteins in various metabolic pathways, and show how proteins interact with one another. These uses of proteomics have made the discipline important in biomarker discovery and drug discovery.

Ethical themes in clinical proteomics

The field of proteomics is beginning to mature and due to its impact on the lives of patients, its responsibilities grow stronger. Guidance and regulations governing the sector must be driven by ethical considerations.

A recent systematic literature review of ethical issues in clinical proteomics published in 2021 in the journal Molecular & Cellular Proteomics highlighted ten ethical themes that they found to be apparent across the clinical proteomics studies included in the review. We discuss each of the ten themes below.

Standards and quality control

In proteomics, the quality of the underlying sciences feeds into the clinical utility of proteomic applications. Therefore, standard operating procedures and quality assurance must be established to enhance the reproducibility and interoperability of proteomic data. It is generally agreed that using incorrect, substandard, or non-validated methods in proteomics is an ethical transgression as well as a technical fault.

Integration of new technology

Proteomics must keep up to date with advances happening in associated scientific fields, particularly in the other omics fields. For example, it has been suggested that blockchain technologies should be leveraged to ensure transparent and secure data access management in proteomics. The most appropriate technologies must be adopted where possible.


There is a level of concern over the possibility of identifying individuals via their proteomic profile. For example, it has been proven that prominent keratin proteins can be used to determine individual profiles. The field must take measures to ensure the privacy of all patients.

Research Ethics

Image Credit: marekuliasz/

Sensitive data/discrimination

Related to privacy is the ethical concern of protecting sensitive data to prevent discrimination. As discussed above, proteomic profiles may be used to identify an individual. Therefore, information derived from proteomics must not be used to cause harm to or put any patient at a disadvantage. Proteomic profiles have the potential to reveal factors such as weight, ethnicity, gender, and allele status. Patients have the right to have this information kept private.

Conflicting rights and duties

It was noted that the duties owed to patients involved in proteomics studies may conflict with those owed to scientific advancement. Further to this, conflicts of interest may exist between the various stakeholders in clinical proteomics. Intellectual property (IP) protections are put in place to further scientific progress, however, current levels of protection make it challenging for scientists to access the work and materials required to make this progress happen.

Beneficence and justice

IP protections are imposing barriers that are particularly challenging to researchers working in low- and middle-income countries where profit-sharing, data-sharing, and benefit-sharing are considered to be prominent ethical issues in the field of proteomics.

Incidental findings

Incidental findings are potentially clinically significant observations that are unexpected and unrelated to the study’s purpose. The potential of incidental findings arising in proteomics studies has raised the question as to how this information should be stored and/or returned to the participants.


National and regional regulations of relevance to proteomics studies must be observed, particularly those relating to informed consent. Additionally, there is a need to update regulations so that they are adequate to address issues of duties owed to patients and scientific progress.

International guidance

The field of clinical proteomics relies on the sharing of findings from studies conducted around the world. Therefore international guidance on ethical issues is required to ensure that patient welfare is assured. International collaboration is needed on ethical issues to establish thorough guidance.

Aims and goals

Guidance on ethics in proteomics should go beyond regulation to consider the fundamental questions facing the growing sector. Questions such as what are the goals of clinical proteomics should be addressed alongside those relating to the ethical aims of the field beyond the aim of avoiding legal liabilities.

As the field continues to grow, these ethical themes must be considered to establish an ethically sound research sector.


Further Reading

Last Updated: Apr 5, 2022

Sarah Moore

Written by

Sarah Moore

After studying Psychology and then Neuroscience, Sarah quickly found her enjoyment for researching and writing research papers; turning to a passion to connect ideas with people through writing.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Moore, Sarah. (2022, April 05). Ethics in Clinical Proteomics. AZoLifeSciences. Retrieved on March 02, 2024 from

  • MLA

    Moore, Sarah. "Ethics in Clinical Proteomics". AZoLifeSciences. 02 March 2024. <>.

  • Chicago

    Moore, Sarah. "Ethics in Clinical Proteomics". AZoLifeSciences. (accessed March 02, 2024).

  • Harvard

    Moore, Sarah. 2022. Ethics in Clinical Proteomics. AZoLifeSciences, viewed 02 March 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.